The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer.  We discuss what that actually  means and some possible implications for clinical practice. 

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

IMHOTEP, PJP, and more

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.